AX-2025-019744 · Melanotan II · Homopeptide lot HOMO-2505-N4086

Section 1

Results

Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	98.87	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.13	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — linear (open-lactam) precursor (+18 Da)	0.49	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	1023.5402	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	1023.5394	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	-0.8	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	90.87	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	89.84	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	10.17	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	9.137	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	91.4	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	3.01	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	5.35	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.77	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.50	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.38	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	9.43	min	9.84 ± 0.25 (normalised)	FAIL
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.12	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	37,788	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [L-Phe7]-diastereomer	0.80	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 37,788, and skew follows the reported asymmetry factor of 1.12. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.49 % impurity against a 98.87 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Melanotan II — main peak	9.43	4,805,388	98.87	—
2	linear (open-lactam) precursor (+18 Da)	8.69	23,816	0.49	+18.011
3	des-acetyl MT-II (−42 Da)	8.95	21,385	0.44	-42.011
4	[L-Phe7]-diastereomer	9.27	4,860	0.10	0.000
5	oxidised Trp (+16 Da)	9.07	2,916	0.06	+15.995
6	MT-II dimer (head-to-tail)	11.78	1,944	0.04	+1023.540
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1023.5402 Da, computed from C50H69N15O9. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1023.5394 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
3+	342.1873	342.1871	-0.0002	9.0
2+	512.7774	512.7770	-0.0004	60.7
1+	1024.5475	1024.5467	-0.0008	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	3.01
Counter-ion (acetate)	ion chromatography	5.35
Residual solvent + inorganic residue	estimated	0.77
Total peptide content	by difference	90.87
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.80	98.87	divergence +0.85 pp vs batch median
Total impurities (% area)	not stated	1.13
Largest single impurity (% area)	not stated	0.49
Water (%)	1.1	3.01
Counter-ion (%)	not stated	5.35
Peptide content (%w/w)	94.1	90.87
Endotoxin (EU/mg)	0.17	0.50
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (2–8 °C, 22 d) → laboratory (courier, ambient, 7 d) → assay.
Assay date: 27 Oct 2025
Submitted to the index: 01 Nov 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 3

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

ms_confirm01 Nov 2025

A reference standard on the same sequence would upgrade this from a good mass to a traceable one. The distinction matters where a result is going to be cited rather than merely read.

nmr_qnmr01 Nov 2025

Mass at -0.8 ppm establishes identity but not content. Absolute content needs a standard or an orthogonal quantitative method, and neither is a mass spectrometer.

sole_source01 Nov 2025

On compounds with a single supplier, independently purchased records are the only thing preventing the evidence base from being entirely supplier-generated. They matter disproportionately there.

Section 7

Related records

Same batch — lot HOMO-2505-N4086 n=4

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2025-019742	HOMO-2505-N4086	VendorInvestigate	2025-Q4	99.38	2.06	96.8	Buyer-sourced	PASS
AX-2026-042385	HOMO-2505-N4086	Nordanalyt	2025-Q4	98.85	2.78	—	Buyer-sourced	PASS
AX-2025-019743	HOMO-2505-N4086	Nordanalyt	2025-Q4	99.02	2.56	100.3	Buyer-sourced	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Melanotan II records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042757	GGPeps	GGPE-2603-P1474	Janoshik	2026-Q3	99.54	6.78	92.0	Buyer-sourced	0	PASS
AX-2026-042756	GGPeps	GGPE-2603-P1474	Nordanalyt	2026-Q3	99.17	7.04	—	Buyer-sourced	0	PASS
AX-2026-042755	GGPeps	GGPE-2603-P1474	Nordanalyt	2026-Q3	99.25	6.58	90.4	Buyer-sourced	0	PASS
AX-2026-042760	GGPeps	GGPE-2603-P1474	Medutest	2026-Q3	99.43	7.02	—	Buyer-sourced	0	PASS
AX-2026-042758	GGPeps	GGPE-2603-P1474	PeptideMeter	2026-Q3	99.23	6.96	—	Buyer-sourced	0	PASS
AX-2026-042759	GGPeps	GGPE-2603-P1474	Janoshik	2026-Q3	99.15	6.71	105.1	Buyer-sourced	0	PASS
AX-2026-042168	JEEP	JEEP-2604-R9103	Nordanalyt	2026-Q2	99.40	5.71	—	Buyer-sourced	0	PASS
AX-2026-042164	JEEP	JEEP-2604-R9103	Janoshik	2026-Q2	99.54	5.23	—	Buyer-sourced	1	MARGINAL

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042437	Retatrutide	HOMO-2605-V4718	Nordanalyt	2026-Q3	98.68	3.67	102.8	Buyer-sourced	PASS
AX-2026-042424	Semaglutide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	PASS
AX-2026-042503	IGF-1 LR3	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	PASS
AX-2026-042492	SS-31 (Elamipretide)	HOMO-2604-D5484	Medutest	2026-Q3	99.93	2.40	—	Buyer-sourced	PASS
AX-2026-042491	SS-31 (Elamipretide)	HOMO-2604-D5484	Kestrel	2026-Q3	99.93	3.24	—	Supplier-supplied	PASS
AX-2026-042473	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.01	5.00	—	Buyer-sourced	PASS
AX-2026-042441	Retatrutide	HOMO-2605-V4718	Medutest	2026-Q3	98.93	4.22	—	Buyer-sourced	PASS
AX-2026-042474	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.18	5.44	—	Buyer-sourced	PASS